Cargando…
Drug repositioning by merging active subnetworks validated in cancer and COVID-19
Computational drug repositioning aims at ranking and selecting existing drugs for novel diseases or novel use in old diseases. In silico drug screening has the potential for speeding up considerably the shortlisting of promising candidates in response to outbreaks of diseases such as COVID-19 for wh...
Autores principales: | Lucchetta, Marta, Pellegrini, Marco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8494853/ https://www.ncbi.nlm.nih.gov/pubmed/34615934 http://dx.doi.org/10.1038/s41598-021-99399-2 |
Ejemplares similares
-
A physarum-inspired prize-collecting steiner tree approach to identify subnetworks for drug repositioning
por: Sun, Yahui, et al.
Publicado: (2016) -
Finding disease modules for cancer and COVID-19 in gene co-expression networks with the Core&Peel method
por: Lucchetta, Marta, et al.
Publicado: (2020) -
Identifying Drug Sensitivity Subnetworks with NETPHIX
por: Kim, Yoo-Ah, et al.
Publicado: (2020) -
Drug Repositioning for COVID-19
por: Benavides-Cordoba, Vicente
Publicado: (2020) -
COVID-19: Analysis of Drug Repositioning Practice
por: Savosina, P. I., et al.
Publicado: (2021)